OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

← The UK Myeloma Society

2025-03-31-accounts

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

Charity number: 1082702

TRUSTEES' REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

THE UK MYELOMA SOCIETY

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

CONTENTS

Page
Reference and administrative details of the Charity, its Trustees and advisers 1
Trustees' report 2 - 5
Independent examiner's report 6
Statement of financial activities 7
Balance sheet 8
Notes to the financial statements 9 - 16

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 MARCH 2025

Trustees Dr N Rabin Dr C Bygrave Dr R Hall Dr J Ashcroft Prof G Cook Prof G Pratt Prof M Kaiser Dr K Ramasamy Dr R Popat Dr M Jenner Dr J Sive Dr S Lawless Dr R Soutar Dr S Lawson J Quinn Dr J Travers C Loughran Dr S Moore Dr T Chan (appointed 13 November 2024)

Charity registered number 1082702 Principal office Pathology Building, Pinderfields Hospital Mid Yorkshire Teaching NHS Trust Aberford Road Wakefield WF1 4DG Independent examiner Menzies LLP Chartered Accountants Magna House 18-32 London Road Staines-Upon-Thames TW18 4BP Bankers Coutts & Co 440 Strand London WC2R 0QS

Page 1

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2025

The Trustees present their annual report together with the financial statements of the Charity for the 1 April 2024 to 31 March 2025.

Objectives and activities

The aims and objectives of the Society are to improve the treatment of patients with myeloma by:

The UKMS had a further active year in pursuit of its’ charitable objectives which are, education, research and advocacy.

To that end three Executive Committee meetings were held 2024; March, June and November.

In keeping with our objectives we have made significant progress in a number of key areas including educational meetings, guidelines and advocacy. There are summarised in the following pages.

Revenue

Education

The Autumn Day was held on 14th November 2024, as a hybrid meeting at the Cavendish Conference Centre and accessed on a virtual platform. The programme theme was ‘UK Myeloma Society at 25: Achievements and Future Directions’and featured Professor Gordon Cook from the University of Leeds. He presented the Michael Morley Lecture on Frailty in Myeloma.

The Spring Day was also a hybrid meeting and was held on 19th March 2025. The theme for this meeting was the ‘Optimising Outcomes in Myeloma’. The plenary lecture was given by Professor Sigurður Kristinsson from the University of Iceland. His talk was entitled, ‘Results from the Iceland screens, treats or prevents multiple myeloma (iStopMM) study.

Travel Bursaries

A total of six travel bursaries for scientific conferences were awarded in 2024 to winning abstracts;

The abstracts were presented at the subsequent Autumn / Spring Days in either November 2024 or March 2025. A corresponding conference report was also written by the bursary recipients from ASH, EHA and IMS which appeared in the UKMS e-newsletter.

Achievements and performance

Education: The annual meetings

Production of two successful and well attended educational hybrid meetings in November 2024 and March 2025. For full programme details, please refer to the section above and the UKMS website.

Page 2

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Travel Bursaries for scientific meetings

The UKMS in collaboration with the Michael Morley Fund awarded 6 bursaries in 2024-25 to support the attendance of investigators, scientists, specialist nurses and pharmacists at ASH (American Society of Haematology), IMS (International Myeloma Society) and EHA (European Haematology Association) meetings in 2024-25. Further details can be found above.

Advocacy

The UKMS members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMS also help develop NICE clinical guidelines and more recently input into NHS England Algorithm.

The Guidelines group

The UKMS Guidelines Group, Chaired by Dr Simon Stern published in 2023 the MGUS good practice paper (GPP). Another GPP on smouldering myeloma was published early in 2024 in the British Journal of Haematology (BJH). GPPs on imaging in myeloma and high risk disease in transplant-eligible myeloma have been completed and accepted by the BSH Haem-onc Task Force and Guidelines Committee. They have both been submitted to the BJH for publication. The aim of the imaging GPP is to produce a document that reinforces the importance of functional imaging both at diagnosis and during the later management of myeloma patients.

Other guidelines are work in progress, notably guidelines on the management of relapsed myeloma and a GPP on MGRS. Other guidelines in their early stages are on the management of myeloma bone disease and screening for amyloid in the outpatient setting.

There have been three important guidelines published in the British Journal of Haematology. These include the good practice papers on imaging and high-risk myeloma and the guideline on the diagnosis and management of monoclonal gammopathy of renal significance. These are also available for viewing on the BSH and UKMS web sites.

The guidelines on relapsed/refractory myeloma and amyloidosis screening; the management of of myeloma bone disease and the use of bispecific antibodies in relapsed/refractory myeloma also in the early stages of planning.

Dr Simon Stern has stepped down as the Chair of the UKMS Guidelines Group and Dr Tracey Chan has taken over as Chair from March 2025.

UKMRA - UK Myeloma Research Alliance

The vision of the UKMRA, Chaired by Dr Rakesh Popat is that all UK based myeloma research is discussed within this forum to allow co-ordination of ideas and further development into national trials to maximise impact. The group met three times over the course of the year, twice virtually with one in-person/ hybrid meeting at the Wellcome Collection in central London on the 14th May 2024. On the 16 - 17 January 2025, the UKMRA held the annual Away Day at the Principle Hotel in York. Around 40 clinical trial investigators from across the UK held their main group meeting as well as a full day dedicated to developing UK Myeloma related clinical trials.

Myeloma Nurse Group

Jackie Quinn has chaired the Nurse group since November 2023.

Projects and discussion for 2024 included;

Myeloma Pharmacy Group

The Pharmacy group, Chaired by Catherine Loughran will promote excellence in the pharmaceutical care of patients with myeloma and support, develop and encourage haematology pharmacists to undertake high quality, audit and research aligned with the UKMS work-plan, and aim to standardise clinical practice across the UK. There are 10 core members. On the 5 November 2024, the group held the Pharmacy Education Day at the Wellcome Collection in central London.

Page 3

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

College of Myeloma (UK)

Prof Gordon Cook created the College of Myeloma (UK) in 2019. He remains the Dean of the College of Myeloma. The College consists of elected fellows representing those who have contributed significantly to the work of the UKMS and to patients with Myeloma through medical science, education and clinical care.

2024 fellows: Sarah Henshaw

Professor Jamie Cavenagh Dr John Ashcroft

Financial review

The UKMS’s policy on its reserves is to maintain a sufficient level of funds to enable operating activities to be supported, taking account of potential risks and contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Income

The Michael Morley Fund

This fund is from a patients estate that is invested on behalf of the UKMS. The Michael Morley funding can be used to fulfil our charitable objectives as agreed with the Michael Morley Trustees.

Investments

CCLA Ethical Charity Investments £56,171

Expenditure

Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Executive Manager, accountants’ fees and employer’s liability insurance). £40,000. Instructed new Accountants, Menzies annual fee £3,200.

UKMS Educational meetings 2024-2025

UKMRA

Breakdown of UKMRA Away Day January 2025 Conference Organiser: Hartley Taylor (HT)

Carried forward from 2024 £4,945
Income: Sponsorship raised for 2025 £36,000 ( J&J, Sanofi, Pfizer £11k each plus GSK £3k)
Total available for 2025 £40,945
Spend: £22,902
HT fees: £16,000
Spend breakdown
Travel £5,239
Venue & hotels £14,375
AV £2,398
HT travel & hotels £890
C/F to 2026 £2,042

Page 4

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

Reserves

The UKMF's reserves remain sound as of 31 March 2025 and were approximately £572,469 (2024: £533,823). The investment is held to generate investment income for use within the Charity along with cash used to continue the Charity activities.

Charitable bequests

Trustees' responsibilities statement

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on their behalf by:

[tide ................................................ A7B83086CBD1420...Signed by: Jolun Aslovoft Dr J Ashcroft Trustee

Date: 22-Jan-2026

Page 5

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

INDEPENDENT EXAMINERS' REPORT

Independent examiner's report to the Trustees of The UK Myeloma Society ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 31 March 2025.

Responsibilities and basis of report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2019.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

  1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: Dated: 23-Jan-2026

Janice Matthews FCA

Menzies LLP

Chartered Accountants Magna House 18-32 London Road Staines-Upon-Thames TW18 4BP

Page 6

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

Note
Income from:
Donations and legacies
3
Investments
4
Total income
Expenditure on:
Raising funds
5
Charitable activities
7
Total expenditure
Net income before net gains on investments
Net gains on investments
12
Net movement in funds
Reconciliation of funds:
Total funds brought forward
Net movement in funds
Total funds carried forward		 Unrestricted
funds
2025
£
183,045
7,167
190,212
1,545
150,361
151,906
38,306
340
38,646
533,823
38,646
572,469		 Total
funds
2025
£
183,045
7,167
190,212
1,545
150,361
151,906
38,306
340
38,646
533,823
38,646
572,469		 Total
funds
2024
£
130,667
6,850
137,517
1,488
116,069
117,557
19,960
15,674
35,634
498,189
35,634
533,823

The Statement of financial activities includes all gains and losses recognised in the year.

The notes on pages 9 to 16 form part of these financial statements.

Page 7

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

BALANCE SHEET AS AT 31 MARCH 2025

2025 2024
Note £ £
Fixed assets
Investments 12 251,532 199,044
251,532 199,044
Current assets
Cash at bank and in hand 334,637 347,353
334,637 347,353
Current liabilities
Creditors: amounts falling due within one year 13 (13,700) (12,574)
Net current assets 320,937 334,779
Total assets less current liabilities 572,469 533,823
Total net assets 572,469 533,823
Charity funds
Designated funds 14 195,361 199,044
General funds 14 377,108 334,779
Total unrestricted funds 14 572,469 533,823
Total funds 572,469 533,823

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

Signed by: ................................................ [tideA7B83086CBD1420... Jol Aslovoft Dr J Ashcroft Trustee

Date: 22-Jan-2026

The notes on pages 9 to 16 form part of these financial statements.

Page 8

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1. General information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the defination of a public benefit entity under FRS 102. The registered office is Pinderfields Hospital, Mid Yorkshire Teaching NHS Trust, Aberford Road, Wakefield, WF1 4DG.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

The UK Myeloma Society meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

2.3 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Page 9

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

2. Accounting policies (continued)

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

2.5 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.6 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as ‘Gains/(Losses) on investments’ in the Statement of Financial Activities.

2.7 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.8 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

Page 10

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

2. Accounting policies (continued)

2.9 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

3. Income from donations and legacies

Donations
Total 2024		 Unrestricted
funds
2025
£
183,045
130,667		 Total
funds
2025
£
183,045
130,667		 Total
funds
2024
£
130,667

4. Investment income

Income from listed investments
Interest receivable
Total 2024		 Unrestricted
funds
2025
£
5,693
1,474
7,167
6,850		 Total
funds
2025
£
5,693
1,474
7,167
6,850		 Total
funds
2024
£
5,366
1,484
6,850

Page 11

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

5. Investment management costs

Investment management fees
Total 2024
Analysis of grants
Bursaries granted
Total 2024		 Unrestricted
funds
2025
£
1,545
1,488
Grants to
Individuals
2025
£
8,151
6,000		 Total
funds
2025
£
1,545
1,488
Total
funds
2025
£
8,151
6,000		 Total
funds
2024
£
1,488
Total
funds
2024
£
6,000

6. Analysis of grants

7. Analysis of expenditure on charitable activities

Summary by fund type

Forum expenses
Website costs
Bank charges
Staff costs (see note 10)
Accountancy
Total 2024		 Unrestricted
funds
2025
£
104,514
5,726
260
34,833
5,028
150,361
116,069		 Total
2025
£
104,514
5,726
260
34,833
5,028
150,361
116,069		 Total
2024
£
69,941
3,422
2,094
37,132
3,480
116,069

Page 12

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

8. Analysis of expenditure by activities

Forum expenses
Website costs
Service charges
Staff costs (see note 10)
Accountancy
Total 2024		 Activities
undertaken
directly
2025
£
96,363
5,726
260
-
-
102,349
69,457		 Grant
funding of
activities
2025
£
8,151
-
-
-
-
8,151
6,000		 Support
costs
2025
£
-
-
-
34,833
5,028
39,861
40,612		 Total
funds
2025
£
104,514
5,726
260
34,833
5,028
150,361
116,069		 Total
funds
2024
£
69,941
3,422
2,094
37,132
3,480
116,069

9. Independent examiner's remuneration

2025 2024
£ £
Fees payable to the Charity's independent examiner for the independent
examination of the Charity's annual accounts 4,800 3,480

10. Staff costs

Wages and salaries
Contribution to defined contribution pension schemes		 2025
£
34,004
829
34,833		 2024
£
36,357
775
37,132

The average number of persons employed by the Charity during the year was as follows:

2025 2024
No. No.
Administration 1 1

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel are the trustees and they received no remuneration during the current or prior year.

Page 13

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

11. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL) .

During the year ended 31 March 2025, expenses totalling £ 2,331 were reimbursed or paid directly to 8 Trustees (2024 - £1,604 to 10 Trustees) .

12. Fixed asset investments

Cost or valuation
At 1 April 2024
Additions
Disposals
Revaluations
Funds withdrawn
Management fees
Dividend and interest income
At 31 March 2025
Net book value
At 31 March 2025
At 31 March 2024
Creditors: Amounts falling due within one year
Other taxation and social security
Pension fund loan payable
Other creditors
Accruals and deferred income		 Listed
investments
£
198,744
79,846
(29,014)
340
-
-
-
249,916
249,916
198,744		 Cash
portfolio
£
300
(19,846)
29,014
-
(12,000)
(1,545)
5,693
1,616
1,616
300
2025
£
1,096
333
7,471
4,800		 Total
£
199,044
60,000
-
340
(12,000)
(1,545)
5,693
251,532
251,532
199,044
2024
£
1,544
314
7,236
3,480
13,700 12,574

13. Creditors: Amounts falling due within one year

Page 14

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

14.
Statement of funds
Statement of funds - current year
Balance at 1
April 2024
£
Income
£
Designated
funds
Michael Morley
Investment
Fund
199,044
5,693
General funds
General Funds
334,779
184,519
Total
Unrestricted
funds
533,823
190,212
Statement of funds - prior year
Balance at
1 April 2023
£
Income
£
Designated
funds
Michael Morley
Investment
Fund
275,492
5,366
General funds
General Funds
222,697
132,151
Total
Unrestricted
funds
498,189
137,517		 Expenditure
£
(1,545)
(150,361)
(151,906)
Expenditure
£
(1,488)
(116,069)
(117,557)		 Transfers
in/out
£
(12,000)
12,000
-
Transfers
in/out
£
(96,000)
96,000
-		 Gains/
(Losses)
£
4,169
(3,829)
340
Gains/
(Losses)
£
15,674
-
15,674		 Balance at 31
March 2025
£
195,361
377,108
572,469
Balance at
31 March
2024
£
199,044
334,779
533,823

The designated fund is used to hold the Charity's investments and generate income.

Page 15

Docusign Envelope ID: 6F1173C7-2796-4256-AF23-634787EA9EE6

THE UK MYELOMA SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

15. Analysis of net assets between funds

Analysis of net assets between funds - current year

Fixed asset investments
Current assets
Creditors due within one year
Total		 Unrestricted
funds
2025
£
251,532
334,637
(13,700)
572,469		 Total
funds
2025
£
251,532
334,637
(13,700)
572,469

Analysis of net assets between funds - prior year

Fixed asset investments
Current assets
Creditors due within one year
Total		 Unrestricted
funds
2024
£
199,044
347,353
(12,574)
533,823		 Total
funds
2024
£
199,044
347,353
(12,574)
533,823

16. Related party transactions

The Charity has not entered into any related party transaction during the year, nor are there any outstanding balances owing between related parties and the Charity at 31 March 2025.

Page 16